Best Sept Since 2010

Today’s RIP: Nike earnings beat, PATH and CRWV climb, Pfizer selling cheap drugs, and the Gov is closing tn. 📰

Author

Kevin Travers
September 30, 2025 • Reading Time: 13 minutes

CLOSING BELL
Best Sept Since 2010

The market climbed on Tuesday to end September in the green, the fifth straight month of gains. It was the best ‘slow’ month of September for 15 years, according to MarketWatch. Nvidia hit an all-time high past $4.5T MC on Tuesday, and smaller names like CoreWeave were on the rise, making gains from datacenter deals in an ongoing AI boom.

Despite the sparks, the lights will shut off at the Fed at midnight tonight, after Congress failed to reach a deal to fund the budget for the first quarter or so of the Fed’s fiscal year, which ends in December.

If only the dealmaker had stepped in! President Trump was focused on drug prices, announcing a new website to buy drugs with cash. Macro numbers Tuesday showed a ‘frozen’ job market, with more openings, less hiring, and falling consumer confidence. 👀

Today’s RIP: Nike earnings beat, PATH and CRWV climb, Pfizer selling cheap drugs, and the Gov is closing tn. 📰

7 of 11 sectors closed green, with healthcare $XLV ( ▲ 2.41% ) leading and energy $XLE ( ▼ 1.06% ) lagging.

EARNINGS
Footwear Giant Saved By Apparel 🎽 

Nike $NKE ( ▲ 0.26% ) shares climbed after the bell, reporting revenue in its first fiscal quarter that beat street estimates.

The shoe-making giant said apparel and equipment helped boost its quarter, according to Chief Elliott Hill. Revenue climbed just 1% to $11.72B after several quarters of decline. Footwear revenue fell.

revnue at Nike finally grew QoQ, according to Fiscal.ai 

"While we're getting wins under our belt, we still have work ahead to get all sports, geographies, and channels on a similar path as we manage a dynamic operating environment," Hill said.

Margins also fell, and profits fell 31%, and CFO Matt Friend said forward progress will “not be linear.” Profit per share still beat estimates at $0.70/share.

STOCKTWITS FEATURES
 New Feature: Autocomplete & Logos for Cashtags Are Here!

Cashtags are how traders talk. And now we’ve made them smarter:

  • Autocomplete cashtags when posting - hit tab or press enter

  • Company logos appear next to cashtags in feeds and posts

  • Toggle logos off anytime in Settings on web or in-app

Cashtags are now easier to spot and tag, making posts and streams clearer at a glance.

STOCKS
Partnerships And Deals Bring In Our Two Top Trending Stories

UiPath $PATH ( ▲ 6.53% ) was trending on Stocktwits Tuesday, climbing 10% after announcing partnerships with Nvidia, OpenAI, and Google. The company offers ‘agentic’ AI agents that can act on their own, and the partnership enables connections with ChatGPT and Gemini tools.

UiPath also announced a similar collaboration with Snowflake $SNOW ( ▲ 0.13% ), a major cloud provider for companies in the U.S.

UiPath watchers were ‘Extremely Bullish’

$CRWV ( ▲ 11.7% ) Coreweave climbed after a $14B deal with Meta, offering its Nvidia chip cloud data center services through 2031.

Before the deal, Microsoft had been CoreWaves’ largest customer, signing $6.5B with OpenAI last week and taking up 70% of the firm’s revenue for its first reported quarter since a March IPO. CoreWeave pulled in $1.2B in its reported Q2, expecting up to $5.15B for the full fiscal year.

Analysts said the recent deals could boost CoreWeaves’ revenue growth beyond Street expectations.

"The $27 billion in new deals from CoreWeave announced this month is that it fuels the view that revenue growth could be much better than previously expected after 2027," Melius Research analysts told WSJ in a note.

MACRO NEWS
Cheap Drug Prices Coming, Which Is Good If You Are Losing Fed Health Benefits 💊 

While the government heads into shutdown, Pfizer shares $PFE ( ▲ 6.83% ) climbed after announcing it would invest $70B in U.S. manufacturing, and offer reduced-rate drugs on a new Trump website.

Trump said the company was granted a three-year grace period from his national security tariff trip for companies that make pharmaceuticals outside of the U.S., which don’t at least try to build domestic production. TrumpRX will allow people to pay cash for certain treatments at a government website, at prices negotiated by the Fed.

“With this deal we’ve signed today, we have satisfied all four of the President’s requirements,” Pfizer Chief Albert Bourla said. “The President is absolutely right—tariffs are the most powerful tool to motivate behavior, and they clearly motivated ours.”

The news lands on the same day that will likely see the last open Government until Congress and the President can agree on short-term funding costs. Ironically, Democrats are fighting for, in part, healthcare support in their standoff in the House and Senate. The Democrats are trying to save Biden-era ACA subsidies, which healthcare cost researcher KFF expects could see out-of-pocket premiums double for millions of Americans.

Up to 4.2 million Americans are expected to become uninsured due to the subsidy cuts, according to KFF.

The White House gave examples for some drugs that it will offer at 50%-85% discounts. One is Eucrisa, a dermatitis treatment, which, without insurance or government subsidies, costs $950 per tube, according to GoodRx. Estimating TrumpRX savings, users can get the drug at $375 on average, compared to the insurance pricing average of $50 a tube, according to Amazon Pharmacy.

The last time the government shut down was 35 days long during the first Trump presidency, caused by an argument over funding a border wall. Simpler times 🧱 

POPS & DROPS
Top Stocktwits News Stories 🗞️ 

  • Ford CEO expects half the EV demand without tax credits.

  • MoonLake rebounded 14% after mixed trial results and analyst downgrades.

  • Nvidia hit $4.5T market cap after OpenAI and Intel deals.

  • Boston Fed backed rate cut if inflation data support easing.

  • Wall Street opposed SEC’s tokenized stock plan amid crypto push.

  • Robinhood hit record high after teasing global prediction market expansion.

  • DraftKings sank 12% after Kalshi’s record sports betting volume.

  • Firefly Aerospace plunged 21% after its rocket exploded.

  • Meta fell after acquiring Rivos to boost AI chip efforts.

  • Wolfspeed surged 50% intraday after finalizing bankruptcy.

Don’t miss a story! Follow @StocktwitsNews for a live feed in real time. ✍️ 

PRESENTED BY STOCKTWITS
Being A CMT Just Got Even Better On Stocktwits

CMT Charterholders or Candidates are eligible for several perks on Stocktwits.

Stocktwits and the CMT Association are teaming up to elevate the visibility of CMT charterholders across global financial markets.

How to qualify + claim your perks: 
If you're a CMT Charterholder or Candidate, opt in here to unlock:

WHAT’S ON DECK
Tomorrow’s Top Things 📋

Economic data: OPEC Meeting (6:00 AM), ADP Nonfarm Employment Change (8:15 AM), S&P Global Manufacturing PMI (9:45 AM), ISM Manufacturing Prices (10:00 AM), Crude Oil Inventories (10:30 AM)📊
Pre-Market Earnings: Conagra Brands ($CAG), Novagold Resources ($NG), and Cal-Maine Foods ($CALM). 🛏️

Links That Don’t Suck 🌐

*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here. 

Get In Touch 📬

Help us deliver the best content possible by completing this brief survey. 📝

Want to see some change? Email Kevin Travers your feedback; follow him on Stocktwits.

Terms & Conditions 📝

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍

Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋

Reply

or to participate.